Immunogenicity developed against therapeutic biologics is undesirable and can have serious clinical consequences. While it remains challenging in assessing immune-related adverse reactions, advances in leveraging clinical pharmacology data have offered an option for evaluating clinical impacts, particularly for potential secondary treatment failures, and more emerging methodologies are becoming available. This presentation will discuss the successes, the remaining challenges, and potential future directions through the lens of a regulatory scientist.